Nebivolol: the somewhat-different β-adrenergic receptor blocker
Although its clinical use in Europe dates almost 10 years, nebivolol is a β-blocker that has
been only recently introduced in the US market. Like carvedilol, nebivolol belongs to the …
been only recently introduced in the US market. Like carvedilol, nebivolol belongs to the …
Beta-blockers in hypertension
CVS Ram - The American journal of cardiology, 2010 - Elsevier
Beta blockers have been used in the treatment of cardiovascular conditions for decades.
Despite a long history and status as a guideline-recommended treatment option for …
Despite a long history and status as a guideline-recommended treatment option for …
Nebivolol: impact on cardiac and endothelial function and clinical utility
JE Toblli, F DiGennaro, JF Giani… - Vascular Health and …, 2012 - Taylor & Francis
Endothelial dysfunction is a systemic pathological state of the endothelium characterized by
a reduction in the bioavailability of vasodilators, essentially nitric oxide, leading to impaired …
a reduction in the bioavailability of vasodilators, essentially nitric oxide, leading to impaired …
Protective effects of nebivolol from oxidative stress to prevent hypertension-related target organ damage
Hypertension is one of the leading risk factors for morbidity and mortality in patients with
cardiovascular and cerebrovascular diseases and renal impairment. It also leads to target …
cardiovascular and cerebrovascular diseases and renal impairment. It also leads to target …
Nebivolol: Haemodynamic effects and clinical significance of combined β-blockade and nitric oxide release
O Kamp, M Metra, S Bugatti, L Bettari, A Dei Cas… - Drugs, 2010 - Springer
Nebivolol is a third-generation β-adrenergic receptor antagonist (β-blocker) with high
selectivity for β 1-adrenergic receptors. In addition, it causes vasodilatation via interaction …
selectivity for β 1-adrenergic receptors. In addition, it causes vasodilatation via interaction …
A Randomized, Double‐Blind, Placebo‐Controlled Parallel‐Group Study to Assess the Efficacy and Safety of Nebivolol, a Novel β‐Blocker, in Patients With Mild to …
RJ Weiss, MA Weber, AA Carr… - The Journal of Clinical …, 2007 - Wiley Online Library
This double‐blind, multicenter, randomized placebo‐controlled study evaluated the
antihypertensive efficacy and safety of nebivolol, a selective β1‐adrenoreceptor blocker with …
antihypertensive efficacy and safety of nebivolol, a selective β1‐adrenoreceptor blocker with …
Изучение цитокиновой активности у больных острым инфарктом миокарда
ИИ Чукаева, НВ Орлова, ЯГ Спирякина… - Российский …, 2010 - cyberleninka.ru
Острый инфаркт миокарда является тяжелым сердечно-сосудистым заболеванием. В
ряде исследований выявлена зависимость течения инфаркта миокарда не только от …
ряде исследований выявлена зависимость течения инфаркта миокарда не только от …
A review of the safety and efficacy of nebivolol in the mildly hypertensive patient
C John - Vascular health and risk management, 2007 - Taylor & Francis
Nebivolol is a third generation beta-blocker, which can be distinguished from other beta-
blockers by its hemodynamic profile. It combines beta-adrenergic blocking activity with a …
blockers by its hemodynamic profile. It combines beta-adrenergic blocking activity with a …
Chronic Nebivolol Treatment Suppresses Endothelin-1–Mediated Vasoconstrictor Tone in Adults With Elevated Blood Pressure
KJ Diehl, BL Stauffer, CA Dow, TD Bammert… - …, 2016 - Am Heart Assoc
Endothelin-1 (ET-1) plays a major role in the pathophysiology of hypertension and its
associated cardiovascular risk. We tested the hypothesis that chronic nebivolol treatment …
associated cardiovascular risk. We tested the hypothesis that chronic nebivolol treatment …
Optimal use of β-blockers in high-risk hypertension: a guide to dosing equivalence
JB McGill - Vascular health and risk management, 2010 - Taylor & Francis
Hypertension is the number one diagnosis made by primary care physicians, placing them
in a unique position to prescribe the antihypertensive agent best suited to the individual …
in a unique position to prescribe the antihypertensive agent best suited to the individual …